60 Degrees Pharmaceuticals (SXTP)

Its best-known asset is tafenoquine, the active ingredient in Arakoda, a malaria prevention product approved in the United States for certain adult patients. Tafenoquine is a long-acting antimalarial, and products based on the compound are central to the company’s pipeline and lifecycle plans. 60 Degrees Pharmaceuticals also evaluates additional tafenoquine-containing products and regimens for infectious disease indications beyond the currently marketed use, subject to clinical development and regulatory review.

The company’s research pipeline extends into other disease areas, including fungal, viral, and vector-borne infections. Its programs include work involving celgosivir, an investigational antiviral candidate that has been studied in relation to dengue and other viral diseases, as well as botanical extracts derived from Australian chestnut trees. As a small biotechnology and specialty pharmaceutical company, 60 Degrees Pharmaceuticals depends on targeted development programs, intellectual property, regulatory progress, and commercial execution rather than a broad portfolio of marketed drugs. Investors typically view SXTP as an early-stage healthcare stock tied to the risks and potential rewards of infectious disease drug development.